Sorafenib induced acneiform eruptions: A case report

Ommurugan Balaji, D. Amita Priya, Navin Patil

Research output: Contribution to journalArticlepeer-review


Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. Sorafenib acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation. Acneiform eruptions are known side effect of epidermal growth factor receptor inhibitors but acneiform eruptions with sorafenib is seldom seen. Hence we report a case of sorafenib - induced acneiform eruptions.

Original languageEnglish
Pages (from-to)6-7
Number of pages2
JournalAsian Journal of Pharmaceutical and Clinical Research
Issue number4
Publication statusPublished - 01-04-2017

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)


Dive into the research topics of 'Sorafenib induced acneiform eruptions: A case report'. Together they form a unique fingerprint.

Cite this